Verrica Pharmaceuticals Inc(NASDAQ:VRCA) 
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; which has completed phase II clinical trial fo...
Website: http://www.verrica.com
Founded: 2013
Full Time Employees: 17
Sector: Healthcare
Industry: Biotechnology
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
revenue: | ||||||||||||||||||||||||||||||||
product revenue | 4,290,000 | 3,722,000 | 3,607,000 | 4,534,000 | 3,422,000 | 315,000 | -1,865,000 | 4,892,000 | 3,232,000 | 1,866,000 | 2,792,000 | |||||||||||||||||||||
license and collaboration revenue | 733,000 | 1,370,000 | 10,737,000 | 8,168,000 | ||||||||||||||||||||||||||||
total revenue | 5,023,000 | 5,092,000 | 14,344,000 | 12,702,000 | 3,439,000 | 344,000 | -1,781,000 | 5,177,000 | 3,826,000 | 1,988,000 | 2,917,000 | |||||||||||||||||||||
yoy | 46.06% | 1380.23% | -905.39% | 145.35% | -10.12% | -82.70% | -161.06% | |||||||||||||||||||||||||
qoq | -1.36% | -64.50% | 12.93% | 269.35% | 899.71% | -119.31% | -134.40% | 35.31% | 92.45% | -31.85% | ||||||||||||||||||||||
operating expenses: | ||||||||||||||||||||||||||||||||
cost of product revenue | 544,000 | 675,000 | 754,000 | 340,000 | 423,000 | 596,000 | 351,000 | 360,000 | 546,000 | 144,000 | 145,000 | |||||||||||||||||||||
cost of license and collaboration revenue | 345,000 | |||||||||||||||||||||||||||||||
selling, general and administrative | 9,989,000 | 8,117,000 | 9,403,000 | 8,852,000 | 8,848,000 | 9,879,000 | 16,083,000 | 16,522,000 | 16,339,000 | 16,995,000 | 20,054,000 | |||||||||||||||||||||
research and development | 3,860,000 | 2,520,000 | 2,205,000 | 1,846,000 | 2,284,000 | 1,167,000 | 2,405,000 | 3,319,000 | 4,948,000 | 5,320,000 | 6,510,000 | 5,725,000 | 2,739,000 | 2,365,000 | 2,946,000 | 4,162,000 | 2,723,000 | 3,357,000 | 3,763,000 | 3,447,000 | 5,362,000 | 2,272,000 | 4,988,000 | 3,521,000 | 4,892,000 | 3,972,000 | 3,049,000 | 3,928,000 | 4,487,000 | 4,804,000 | 3,484,000 | 3,609,000 |
total operating expenses | 14,738,000 | 12,284,000 | 12,717,000 | 11,192,000 | 11,569,000 | 11,754,000 | 18,923,000 | 20,383,000 | 22,425,000 | 25,124,000 | 26,834,000 | 11,798,000 | 7,126,000 | 6,012,250 | 6,871,000 | 9,335,000 | 7,841,000 | 8,470,000 | 11,768,000 | 10,731,000 | 11,940,000 | 12,033,000 | 9,637,000 | 8,631,000 | 9,880,000 | 7,990,000 | 6,543,000 | 7,521,000 | 8,026,000 | 6,686,000 | 7,165,000 | 6,112,000 |
income from operations | -9,715,000 | -7,192,000 | 1,627,000 | 1,510,000 | -8,130,000 | -11,410,000 | -20,704,000 | -15,206,000 | -18,599,000 | -23,136,000 | -23,917,000 | -11,616,000 | -7,089,000 | -6,211,000 | 1,448,000 | -9,121,000 | -7,410,000 | -8,470,000 | -11,768,000 | -10,731,000 | 60,000 | -12,033,000 | -9,637,000 | -8,631,000 | -9,880,000 | -7,990,000 | -6,543,000 | -7,521,000 | -8,026,000 | -6,686,000 | -7,165,000 | -6,112,000 |
yoy | 19.50% | -36.97% | -107.86% | -109.93% | -56.29% | -50.68% | -13.43% | 30.91% | 162.36% | 272.50% | -1751.73% | 27.35% | -4.33% | -26.67% | -112.30% | -15.00% | -12450.00% | -29.61% | 22.11% | 24.33% | -100.61% | 50.60% | 47.29% | 14.76% | 23.10% | 19.50% | -8.68% | 23.05% | ||||
qoq | 35.08% | -542.04% | 7.75% | -118.57% | -28.75% | -44.89% | 36.16% | -18.24% | -19.61% | -3.27% | 105.90% | 63.86% | 14.14% | -528.94% | -115.88% | 23.09% | -12.51% | -28.03% | 9.66% | -17985.00% | -100.50% | 24.86% | 11.66% | -12.64% | 23.65% | 22.12% | -13.00% | -6.29% | 20.04% | -6.69% | 17.23% | |
operating margin % | -193.41% | -141.24% | 11.34% | 11.89% | -236.41% | -3316.86% | 1162.49% | -293.72% | -486.12% | -1163.78% | -819.92% | -Infinity% | -Infinity% | -Infinity% | Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% |
other income: | ||||||||||||||||||||||||||||||||
interest income | 201,000 | 205,000 | 159,000 | 228,000 | 337,000 | 205,000 | 221,000 | 393,000 | 598,000 | 792,000 | 822,000 | 626,000 | 500,000 | 286,000 | 148,000 | 20,000 | 22,000 | 27,000 | 31,000 | 33,000 | 32,000 | 48,000 | 69,000 | 126,000 | 278,000 | 354,000 | 453,000 | 523,000 | 547,000 | 610,000 | 427,000 | 153,000 |
interest expense | -160,000 | -1,314,000 | -2,094,000 | -2,131,000 | -2,203,000 | -2,349,000 | -2,376,000 | -2,368,000 | -2,319,000 | -2,305,000 | -1,657,000 | -81,000 | -1,066,000 | -1,082,000 | -1,097,000 | -1,092,000 | -1,077,000 | -1,028,000 | -991,000 | -918,000 | -904,000 | -220,000 | ||||||||||
change in fair value of derivative liability | 1,762,000 | 34,000 | 598,000 | 254,000 | ||||||||||||||||||||||||||||
other expense | -8,000 | -2,000 | -1,000 | -1,000 | -5,000 | -11,000 | -1,000 | -1,000 | -3,000 | -1,000 | ||||||||||||||||||||||
total other income | 33,000 | -1,467,000 | -2,156,000 | -1,980,000 | -1,732,000 | 60,500 | -885,000 | 626,000 | 500,000 | -996,000 | -944,000 | -849,000 | -778,000 | 58,000 | 353,000 | 453,000 | 520,000 | 547,000 | 610,000 | 426,000 | 153,000 | |||||||||||
net income | -9,682,000 | -8,074,000 | -274,000 | 204,000 | -9,742,000 | -16,202,000 | -22,860,000 | -17,186,000 | -20,331,000 | -24,614,000 | -24,802,000 | -10,990,000 | -6,589,000 | -5,932,000 | 83,000 | -10,168,000 | -8,470,000 | -9,540,000 | -12,829,000 | -11,775,000 | -936,000 | -12,977,000 | -10,486,000 | -9,409,000 | -9,822,000 | -7,637,000 | -6,090,000 | -7,001,000 | -7,479,000 | -6,076,000 | -6,739,000 | -5,959,000 |
yoy | -0.62% | -50.17% | -98.80% | -101.19% | -52.08% | -34.18% | -7.83% | 56.38% | 208.56% | 314.94% | -29981.93% | 8.08% | -22.21% | -37.82% | -100.65% | -13.65% | 804.91% | -26.49% | 22.34% | 25.15% | -90.47% | 69.92% | 72.18% | 34.40% | 31.33% | 25.69% | -9.63% | 17.49% | ||||
qoq | 19.92% | 2846.72% | -234.31% | -102.09% | -39.87% | -29.13% | 33.02% | -15.47% | -17.40% | -0.76% | 125.68% | 66.79% | 11.08% | -7246.99% | -100.82% | 20.05% | -11.22% | -25.64% | 8.95% | 1158.01% | -92.79% | 23.76% | 11.45% | -4.20% | 28.61% | 25.40% | -13.01% | -6.39% | 23.09% | -9.84% | 13.09% | |
net income margin % | -192.75% | -158.56% | -1.91% | 1.61% | -283.28% | -4709.88% | 1283.55% | -331.97% | -531.39% | -1238.13% | -850.26% | -Infinity% | -Infinity% | -Infinity% | Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% |
net income per share | -0.45 | -0.65 | -0.03 | 0.02 | -0.1 | -0.18 | -0.49 | -0.37 | -0.44 | -0.24 | -0.15 | -0.37 | -0.31 | -0.35 | -0.47 | -0.43 | -0.04 | -0.52 | -0.42 | -0.38 | -0.39 | -0.3 | -0.24 | -0.28 | -0.3 | -0.11 | -0.27 | -1.04 | ||||
weighted-average common shares outstanding, basic and diluted | 21,305,025 | 10,652,367 | 9,490,083 | 94,837,343 | 51,808,228 | 46,805,427 | 46,502,274 | 46,483,669 | 45,342,451 | 45,916,867 | 43,023,379 | 34,163,437 | 27,519,053 | 27,519,053 | 27,044,462 | 27,516,477 | 27,513,665 | 25,602,404 | 24,995,556 | 24,988,939 | 24,965,634 | 24,964,167 | 24,897,889 | 24,893,036 | 24,875,573 | 24,857,771 | 14,662,751 | 24,847,512 | 5,751,326 | |||
cost of collaboration revenue | 130,750 | 355,000 | 154,000 | 14,000 | 29,000 | 84,000 | 182,000 | 592,000 | 128,000 | 125,000 | 136,000 | 68,000 | ||||||||||||||||||||
total other expense | -882,000 | -1,901,000 | -1,306,000 | -1,612,000 | 279,000 | -1,365,000 | -1,047,000 | -1,060,000 | -1,070,000 | -1,061,000 | -1,044,000 | |||||||||||||||||||||
weighted-average common shares outstanding, basic | 9,488,055 | |||||||||||||||||||||||||||||||
weighted-average common shares outstanding, diluted | 9,490,600 | |||||||||||||||||||||||||||||||
collaboration revenue | 17,000 | 29,000 | 84,000 | 285,000 | 594,000 | 122,000 | 125,000 | 182,000 | 37,000 | |||||||||||||||||||||||
loss on extinguishment of debt | -1,437,000 | |||||||||||||||||||||||||||||||
other income | -12,250 | -50,000 | -12,750 | 5,000 | ||||||||||||||||||||||||||||
net income per share | -0.45 | -0.65 | -0.03 | 0.02 | -0.1 | -0.18 | -0.49 | -0.37 | -0.44 | -0.24 | -0.15 | -0.37 | -0.31 | -0.35 | -0.47 | -0.43 | -0.04 | -0.52 | -0.42 | -0.38 | -0.39 | -0.3 | -0.24 | -0.28 | -0.3 | -0.11 | -0.27 | -1.04 | ||||
basic | -0.235 | -0.54 | -0.145 | |||||||||||||||||||||||||||||
diluted | -0.235 | -0.54 | -0.145 | |||||||||||||||||||||||||||||
weighted-average common shares outstanding | ||||||||||||||||||||||||||||||||
basic | 46,073,932 | 40,304,923 | ||||||||||||||||||||||||||||||
diluted | 46,073,932 | 44,656,172 | ||||||||||||||||||||||||||||||
other comprehensive gain: | ||||||||||||||||||||||||||||||||
unrealized gain on marketable securities | 35 | -33 | -4 | 2 | -5 | -26 | 12 | -7 | -11 | 27 | 28 | |||||||||||||||||||||
comprehensive income | -10,595.25 | -24,802 | -4,638.75 | 118 | ||||||||||||||||||||||||||||
general and administrative | 5,937,000 | 4,319,000 | 3,189,000 | 3,925,000 | 5,173,000 | 5,118,000 | 5,113,000 | 8,005,000 | 7,284,000 | 6,578,000 | 9,761,000 | 4,649,000 | 5,110,000 | 4,988,000 | 4,018,000 | 3,494,000 | 3,593,000 | 3,539,000 | 1,882,000 | 3,681,000 | 2,503,000 | |||||||||||
other comprehensive loss: | ||||||||||||||||||||||||||||||||
unrealized loss on marketable securities | -2 | -27 | -1 | -10 | -7 | |||||||||||||||||||||||||||
comprehensive loss | -10,990 | -6,589 | -10,170 | -8,503 | -9,567 | -12,830 | -11,779 | -934 | -12,982 | -10,512 | -9,397 | -9,822 | -7,644 | -6,101 | -6,974 | -7,451 | -6,086 | -6,746 | ||||||||||||||
license revenue | 2,241,000 | 8,319,000 | 214,000 | 431,000 | 12,000,000 | |||||||||||||||||||||||||||
interest expense - related party |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | ||||||||||||||||||||||||||||
current assets: | ||||||||||||||||||||||||||||
cash | 20,600,000 | |||||||||||||||||||||||||||
accounts receivable | 7,724,000 | 7,047,000 | 9,193,000 | 5,607,000 | 7,002,000 | 4,248,000 | 3,946,000 | |||||||||||||||||||||
collaboration receivable, billed and unbilled | 89,000 | 282,000 | ||||||||||||||||||||||||||
deferred r&d services, current portion | 1,374,000 | 1,959,000 | ||||||||||||||||||||||||||
inventory | 1,974,000 | 2,304,000 | 2,522,000 | 2,459,000 | 2,499,000 | 1,022,000 | 279,000 | |||||||||||||||||||||
prepaid expenses and other current assets | 2,368,000 | 3,586,000 | 1,492,000 | 1,767,000 | 2,344,000 | 2,545,000 | 3,066,000 | |||||||||||||||||||||
total current assets | 34,129,000 | 36,275,000 | 36,781,000 | 39,474,000 | 61,376,000 | 77,530,000 | 91,725,000 | 56,777,000 | 63,097,000 | 39,115,000 | 43,395,000 | 57,341,000 | 65,772,000 | 74,328,000 | 83,158,000 | 93,374,000 | 102,046,000 | 67,650,000 | 73,974,000 | 83,338,000 | 90,647,000 | 64,983,000 | 74,040,000 | 79,739,000 | 84,677,000 | 91,152,000 | 98,677,000 | 104,590,000 |
property and equipment | 191,000 | 225,000 | 315,000 | 537,000 | 937,000 | 1,052,000 | 3,558,000 | 3,688,000 | 3,801,000 | 3,887,000 | 4,018,000 | 4,044,000 | 4,155,000 | 3,894,000 | 3,668,000 | 3,648,000 | 3,329,000 | 3,102,000 | 2,708,000 | 2,517,000 | 2,375,000 | 2,090,000 | 255,000 | |||||
operating lease right-of-use asset | 463,000 | 616,000 | 690,000 | 764,000 | 1,082,000 | 1,158,000 | 1,339,000 | 1,300,000 | 1,372,000 | 1,443,000 | 1,513,000 | 1,582,000 | 1,548,000 | 1,608,000 | 1,666,000 | 1,723,000 | 1,780,000 | 1,836,000 | 1,891,000 | 45,000 | 111,000 | 178,000 | 245,000 | 275,000 | ||||
finance lease right-of-use asset | 1,009,000 | 1,050,000 | 945,000 | 1,027,000 | 2,460,000 | 1,405,000 | ||||||||||||||||||||||
deferred r&d services, non-current portion | 2,354,000 | 2,354,000 | ||||||||||||||||||||||||||
other non-current assets | 640,000 | 376,000 | 376,000 | 376,000 | 452,000 | 452,000 | 526,000 | 436,000 | 369,000 | 276,000 | 221,000 | 469,000 | 142,000 | 295,000 | 264,000 | 285,000 | 947,000 | 1,566,000 | 1,363,000 | 1,381,000 | 1,375,000 | |||||||
total assets | 38,786,000 | 40,896,000 | 39,107,000 | 42,178,000 | 66,307,000 | 81,597,000 | 97,148,000 | 62,201,000 | 68,639,000 | 44,721,000 | 49,147,000 | 63,436,000 | 71,617,000 | 80,125,000 | 88,756,000 | 99,030,000 | 108,102,000 | 74,154,000 | 79,936,000 | 87,236,000 | 94,442,000 | 68,424,000 | 76,074,000 | 81,250,000 | 85,979,000 | 91,906,000 | 98,805,000 | 104,716,000 |
liabilities and stockholders’ equity | ||||||||||||||||||||||||||||
current liabilities: | ||||||||||||||||||||||||||||
accounts payable | 2,193,000 | 1,585,000 | 2,321,000 | 1,443,000 | 2,527,000 | 2,464,000 | 1,925,000 | 2,057,000 | 575,000 | 507,000 | 137,000 | 714,000 | 531,000 | 845,000 | 904,000 | 783,000 | 878,000 | 348,000 | 179,000 | 1,297,000 | 1,103,000 | 1,185,000 | 1,010,000 | 1,467,000 | 1,136,000 | 922,000 | 1,067,000 | 1,081,000 |
accrued expenses and other current liabilities | 12,251,000 | 12,600,000 | 13,101,000 | 14,484,000 | 15,828,000 | 13,860,000 | 9,102,000 | 3,365,000 | 1,766,000 | 2,655,000 | 2,650,000 | 2,414,000 | 2,014,000 | 3,266,000 | 3,877,000 | 3,252,000 | 2,881,000 | 3,114,000 | 3,099,000 | 2,557,000 | 2,066,000 | |||||||
deferred revenue | 1,031,000 | 1,564,000 | 481,000 | 500,000 | 500,000 | |||||||||||||||||||||||
operating lease liability | 348,000 | 335,000 | 328,000 | 321,000 | 331,000 | 324,000 | 316,000 | 309,000 | 302,000 | 297,000 | 291,000 | 283,000 | 250,000 | 245,000 | 239,000 | 235,000 | 230,000 | 198,000 | 245,000 | 124,000 | 133,000 | 130,000 | 127,000 | 124,000 | 122,000 | |||
finance lease liability | 396,000 | 366,000 | 318,000 | 327,000 | 679,000 | 376,000 | 31,000 | |||||||||||||||||||||
total current liabilities | 16,219,000 | 28,908,000 | 29,222,000 | 29,396,000 | 19,365,000 | 17,024,000 | 11,374,000 | 5,731,000 | 2,643,000 | 3,459,000 | 3,078,000 | 45,711,000 | 44,800,000 | 46,055,000 | 46,374,000 | 45,282,000 | 44,658,000 | 39,475,000 | 39,003,000 | 38,698,000 | 3,302,000 | 3,351,000 | 4,330,000 | 4,281,000 | 3,062,000 | 2,477,000 | 2,451,000 | 3,125,000 |
r&d funding liability | 5,814,000 | 4,688,000 | ||||||||||||||||||||||||||
total liabilities | 22,731,000 | 57,936,000 | 56,591,000 | 60,754,000 | 64,799,000 | 61,834,000 | 54,845,000 | 6,801,000 | 3,793,000 | 4,688,000 | 4,382,000 | 47,103,000 | 46,199,000 | 47,520,000 | 47,904,000 | 46,874,000 | 46,292,000 | 41,168,000 | 40,754,000 | 38,773,000 | 37,834,000 | 3,409,000 | 4,421,000 | 4,405,000 | 3,218,000 | 2,477,000 | 2,451,000 | 3,125,000 |
commitments and contingencies | ||||||||||||||||||||||||||||
stockholders’ equity: | ||||||||||||||||||||||||||||
preferred stock, 0.0001 par value... | ||||||||||||||||||||||||||||
common stock, 0.0001 par value... | 2,000 | 1,000 | 1,000 | 9,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 |
treasury stock | ||||||||||||||||||||||||||||
additional paid-in capital | 350,648,000 | 299,798,000 | 299,080,000 | 298,184,000 | 252,287,000 | 250,207,000 | 248,133,000 | 236,428,000 | 234,884,000 | 203,482,000 | 202,311,000 | 173,998,000 | 172,913,000 | 171,597,000 | 170,277,000 | 168,751,000 | 166,626,000 | 136,868,000 | 130,528,000 | 128,851,000 | 127,599,000 | 126,594,000 | 125,178,000 | 124,269,000 | 123,211,000 | 122,526,000 | 123,365,000 | 121,856,000 |
accumulated deficit | -334,595,000 | -316,839,000 | -316,565,000 | -316,769,000 | -250,779,000 | -230,448,000 | -205,834,000 | -181,032,000 | -170,042,000 | -163,453,000 | -157,521,000 | -157,604,000 | -147,436,000 | -138,966,000 | -129,426,000 | -116,597,000 | -104,822,000 | -103,886,000 | -90,909,000 | -80,423,000 | -71,014,000 | -61,192,000 | -53,555,000 | -47,465,000 | -40,464,000 | -33,083,000 | -27,007,000 | -20,268,000 |
total stockholders’ equity | 16,055,000 | 1,508,000 | 19,763,000 | 42,303,000 | 55,400,000 | 64,846,000 | 40,033,000 | 44,765,000 | 16,333,000 | 25,418,000 | 32,605,000 | 40,852,000 | 52,156,000 | 61,810,000 | 32,986,000 | 39,182,000 | 48,463,000 | 56,608,000 | 65,015,000 | 71,653,000 | 76,845,000 | 82,761,000 | 89,429,000 | 96,354,000 | 101,591,000 | |||
total liabilities and stockholders’ equity | 38,786,000 | 66,307,000 | 81,597,000 | 97,148,000 | 62,201,000 | 68,639,000 | 44,721,000 | 49,147,000 | 63,436,000 | 71,617,000 | 80,125,000 | 88,756,000 | 99,030,000 | 108,102,000 | 74,154,000 | 79,936,000 | 87,236,000 | 94,442,000 | 68,424,000 | 76,074,000 | 81,250,000 | 85,979,000 | ||||||
cash and cash equivalents | 21,097,000 | 15,396,000 | 29,595,000 | 48,939,000 | 69,547,000 | 84,308,000 | 55,140,000 | 59,952,000 | 34,273,000 | 32,473,000 | 5,430,000 | 10,407,000 | 15,752,000 | 20,442,000 | 24,706,000 | 44,101,000 | 10,686,000 | 17,198,000 | 48,932,000 | 54,486,000 | 9,241,000 | 10,600,000 | 19,852,000 | 24,427,000 | 10,271,000 | 38,311,000 | 103,149,000 | |
liabilities and stockholders’ deficit | ||||||||||||||||||||||||||||
current portion of long-term debt | 12,458,000 | 12,673,000 | 12,821,000 | |||||||||||||||||||||||||
derivative liability | 1,762,000 | 1,796,000 | 2,394,000 | |||||||||||||||||||||||||
long term debt | 21,619,000 | 24,578,000 | 27,809,000 | 42,848,000 | 42,874,000 | 42,401,000 | ||||||||||||||||||||||
stockholders’ deficit: | ||||||||||||||||||||||||||||
total stockholders’ deficit | -17,040,000 | -17,484,000 | -18,576,000 | |||||||||||||||||||||||||
total liabilities and stockholders’ deficit | 40,896,000 | 39,107,000 | 42,178,000 | |||||||||||||||||||||||||
license and collaboration receivable, billed and unbilled | 8,178,000 | |||||||||||||||||||||||||||
unbilled collaboration revenue | 46,000 | 592,000 | 168,000 | |||||||||||||||||||||||||
subscription receivable | -4,000 | -446,000 | -410,000 | |||||||||||||||||||||||||
collaboration revenue receivable | 388,000 | |||||||||||||||||||||||||||
unbilled revenue | 126,000 | |||||||||||||||||||||||||||
unbilled revenue receivable | 173,000 | 56,000 | ||||||||||||||||||||||||||
prepaid expenses and other assets | 1,464,000 | 3,089,000 | 4,355,000 | 3,522,000 | 2,725,000 | 3,437,000 | 3,974,000 | 3,663,000 | 3,245,000 | 2,860,000 | 2,180,000 | 2,093,000 | 3,716,000 | 2,265,000 | 2,966,000 | 2,962,000 | 985,000 | 1,389,000 | 1,343,000 | 1,702,000 | 1,441,000 | |||||||
marketable securities | 6,981,000 | 8,968,000 | 11,497,000 | 54,602,000 | 59,053,000 | 65,423,000 | 43,585,000 | 54,784,000 | 54,683,000 | 30,690,000 | 33,896,000 | 52,776,000 | 60,478,000 | 58,902,000 | 58,855,000 | 79,538,000 | 58,664,000 | |||||||||||
unbilled collaboration revenue receivable | 99,000 | |||||||||||||||||||||||||||
financing lease liability | 7,000 | 6,000 | 6,000 | 6,000 | 7,000 | |||||||||||||||||||||||
debt | 42,293,000 | 41,999,000 | 41,693,000 | |||||||||||||||||||||||||
accumulated other comprehensive loss | -29,000 | -64,000 | -62,000 | -17,000 | -7,000 | |||||||||||||||||||||||
unbilled receivable | 419,000 | 218,000 | 431,000 | |||||||||||||||||||||||||
restricted cash | 40,000,000 | 40,000,000 | ||||||||||||||||||||||||||
accumulated other comprehensive gain | -29,000 | -2,000 | -1,000 | 3,000 | 1,000 | 6,000 | 32,000 | 20,000 | 20,000 | 27,000 | 38,000 | 11,000 | ||||||||||||||||
short term debt | 41,348,000 | 41,005,000 | ||||||||||||||||||||||||||
license receivable | 11,500,000 | |||||||||||||||||||||||||||
current debt | 40,669,000 | 35,315,000 | 34,980,000 | 34,720,000 | ||||||||||||||||||||||||
other liabilities | 75,000 | 75,000 | ||||||||||||||||||||||||||
long-term debt | 34,434,000 | |||||||||||||||||||||||||||
deposits | 1,240,000 | 34,000 | 14,000 | 14,000 | 499,000 | 14,000 | 14,000 | |||||||||||||||||||||
accrued expenses | 2,036,000 | 3,193,000 | 2,684,000 | 1,804,000 | 1,517,000 | 1,346,000 | 2,008,000 | |||||||||||||||||||||
accounts payable and accrued expenses - related party | 6,000 | 38,000 | 38,000 | 36,000 | ||||||||||||||||||||||||
property, plant and equipment | 1,822,000 | 1,252,000 | 1,013,000 | 114,000 | 112,000 | |||||||||||||||||||||||
due to related party | ||||||||||||||||||||||||||||
other receivable - related party | 6,000 | |||||||||||||||||||||||||||
liabilities, convertible preferred stock and stockholders’ equity | ||||||||||||||||||||||||||||
convertible preferred stock - series a - 0 and 21,302,972 shares authorized, issued and outstanding as of december 31, 2018 and december 31, 2017, respectively | ||||||||||||||||||||||||||||
convertible preferred stock - series b - 0 and 1,937,984 shares authorized, issued and outstanding as of december 31, 2018 and december 31, 2017, respectively | ||||||||||||||||||||||||||||
total convertible preferred stock | ||||||||||||||||||||||||||||
stockholders’ equity | ||||||||||||||||||||||||||||
total liabilities, convertible preferred stock and stockholders’ equity | 91,906,000 | 98,805,000 | 104,716,000 | |||||||||||||||||||||||||
convertible preferred stock - series a - 0 and 21,302,972 shares authorized, issued and outstanding as of september 30, 2018 and december 31, 2017, respectively | ||||||||||||||||||||||||||||
convertible preferred stock - series b - 0 and 1,937,984 shares authorized, issued and outstanding as of september 30, 2018 and december 31, 2017, respectively | ||||||||||||||||||||||||||||
convertible preferred stock - series a - 0 and 21,302,972 shares authorized, issued and outstanding as of june 30, 2018 and december 31, 2017, respectively | ||||||||||||||||||||||||||||
convertible preferred stock - series b - 0 and 1,937,984 shares authorized, issued and outstanding as of june 30, 2018 and december 31, 2017, respectively |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash flows from operating activities | |||||||||||||||||||||||||||||
net loss | -9,682,000 | -8,074,000 | -274,000 | -16,202,000 | -22,860,000 | -17,186,000 | -20,331,000 | -24,614,000 | -24,802,000 | -10,990,000 | -6,589,000 | -5,932,000 | 83,000 | -10,168,000 | -8,470,000 | -9,540,000 | -12,829,000 | -11,775,000 | -936,000 | -12,977,000 | -10,486,000 | -9,409,000 | -9,822,000 | -7,637,000 | -6,090,000 | -7,001,000 | -7,479,000 | -6,076,000 | -6,739,000 |
adjustments to reconcile net loss to net cash from operating activities: | |||||||||||||||||||||||||||||
stock-based compensation | 897,000 | 686,000 | 718,000 | 756,000 | 2,108,000 | 2,228,000 | 2,072,000 | 2,075,000 | 9,663,000 | 1,544,000 | 1,094,000 | 1,171,000 | 1,413,000 | 1,085,000 | 1,316,000 | 1,321,000 | 1,481,000 | 1,848,000 | 1,403,000 | 6,340,000 | 1,231,000 | 1,252,000 | 998,000 | 802,000 | 905,000 | 846,000 | 780,000 | -848,000 | 1,516,000 |
depreciation expense | 17,000 | 14,000 | 23,000 | 54,000 | 61,000 | 101,000 | 126,000 | 131,000 | 133,000 | 135,000 | 131,000 | 131,000 | 127,000 | 98,000 | 98,000 | 142,000 | 54,000 | 37,000 | 11,000 | 12,000 | 5,000 | 12,000 | 14,000 | 26,000 | 16,000 | 11,000 | 11,000 | 10,000 | 5,000 |
non-cash interest expense | 400,000 | 716,000 | 572,000 | ||||||||||||||||||||||||||
loss on termination of financing lease | 10,000 | -2,000 | -1,000 | ||||||||||||||||||||||||||
amortization of operating lease right-of-use asset | 77,000 | 76,000 | 74,000 | 62,000 | 93,000 | 77,000 | 76,000 | ||||||||||||||||||||||
amortization of finance lease right-of-use asset | 100,000 | 100,000 | 87,000 | 137,000 | 188,000 | 156,000 | 138,000 | ||||||||||||||||||||||
change in deferred r&d services and r&d funding liability | 1,332,000 | ||||||||||||||||||||||||||||
non-cash r&d expense related to torii warrant vesting | 106,000 | ||||||||||||||||||||||||||||
change in fair value of derivative liability | -1,762,000 | -34,000 | |||||||||||||||||||||||||||
changes in operating assets and liabilities: | |||||||||||||||||||||||||||||
prepaid expenses and other assets | 433,000 | 1,012,000 | -2,094,000 | 371,000 | 113,000 | -337,000 | -1,275,000 | -420,000 | -1,884,000 | 1,625,000 | 1,266,000 | -720,000 | -784,000 | 511,000 | 537,000 | -310,000 | -451,000 | 205,000 | 13,000 | -87,000 | 1,582,000 | -1,410,000 | 701,000 | -2,000 | -1,977,000 | 404,000 | -46,000 | 373,000 | -261,000 |
collaboration receivable, billed and unbilled | 48,000 | 145,000 | |||||||||||||||||||||||||||
inventory | 262,000 | 218,000 | |||||||||||||||||||||||||||
accounts payable | 121,000 | 487,000 | -736,000 | 931,000 | -169,000 | -1,382,000 | 52,000 | 578,000 | 121,000 | 1,488,000 | 14,000 | 370,000 | -577,000 | 183,000 | -314,000 | -25,000 | 87,000 | -90,000 | 525,000 | 168,000 | -1,118,000 | 194,000 | -82,000 | 174,000 | 56,000 | -182,000 | 215,000 | -145,000 | 341,000 |
deferred revenue | 249,000 | -782,000 | 1,083,000 | 0 | 0 | 0 | -500,000 | 0 | |||||||||||||||||||||
accounts receivable | -2,464,000 | 1,787,000 | 2,146,000 | -201,000 | 10,178,000 | -3,024,000 | -2,753,000 | 86,000 | |||||||||||||||||||||
accrued expenses and other current liabilities | -586,000 | -400,000 | -501,000 | -5,180,000 | 896,000 | 2,022,000 | 1,968,000 | 5,120,000 | 5,458,000 | 1,647,000 | -934,000 | 72,000 | 553,000 | 545,000 | -1,425,000 | -700,000 | 669,000 | 448,000 | -209,000 | 442,000 | 519,000 | 279,000 | |||||||
operating lease liability | -83,000 | -82,000 | -79,000 | -67,000 | -97,000 | -79,000 | -79,000 | -67,000 | -77,000 | -73,000 | -74,000 | -70,000 | -68,000 | -66,000 | -60,000 | -57,000 | -57,000 | -56,000 | -27,000 | -105,000 | -38,000 | -32,000 | -32,000 | -31,000 | -30,000 | -30,000 | -28,000 | ||
net cash from operating activities | -9,163,000 | -4,591,000 | 9,685,000 | -16,064,000 | -8,558,000 | -16,358,000 | -19,947,000 | -14,507,000 | -14,811,000 | -4,669,000 | -4,590,000 | -4,954,000 | 1,825,000 | -7,181,000 | -8,340,000 | -8,698,000 | -10,598,000 | 2,499,000 | -10,785,000 | -6,099,000 | -7,608,000 | -8,594,000 | -7,906,000 | -8,213,000 | -7,228,000 | -5,050,000 | -6,917,000 | -6,903,000 | -5,137,000 |
capital expenditures | 0 | 0 | 0 | 0 | -16,000 | 0 | -227,000 | -65,000 | -59,000 | -11,000 | -66,000 | -77,000 | -154,000 | -5,000 | -237,000 | -39,000 | -296,000 | -311,000 | 0 | -111,000 | -116,000 | -699,000 | -3,000 | 0 | 0 | -151,000 | -13,000 | ||
free cash flows | -9,163,000 | -4,591,000 | 9,685,000 | -16,064,000 | -8,574,000 | -16,358,000 | -14,734,000 | -14,876,000 | -4,728,000 | -4,601,000 | -5,020,000 | 1,748,000 | -7,335,000 | -8,345,000 | -8,935,000 | -10,637,000 | 2,203,000 | -11,096,000 | -6,099,000 | -7,719,000 | -8,710,000 | -8,605,000 | -8,216,000 | -7,228,000 | -5,050,000 | -7,054,000 | -5,150,000 | ||
cash flows from investing activities | |||||||||||||||||||||||||||||
net cash from investing activities | 8,000 | -16,000 | -227,000 | -65,000 | -59,000 | -11,000 | 6,754,000 | 2,069,000 | 2,205,000 | 43,013,000 | 4,011,000 | 6,291,000 | -22,135,000 | 10,835,000 | -858,000 | -24,126,000 | 3,130,000 | 18,274,000 | 6,650,000 | -2,028,000 | 263,000 | 21,070,000 | -21,146,000 | -58,637,000 | |||||
cash flows from financing activities | |||||||||||||||||||||||||||||
repayment of debt | -870,000 | -3,890,000 | 0 | ||||||||||||||||||||||||||
repayment of finance lease | -111,000 | -106,000 | -94,000 | -177,000 | -156,000 | ||||||||||||||||||||||||
payment of equity issuance costs | -9,000 | ||||||||||||||||||||||||||||
net cash from financing activities | -120,000 | 13,641,000 | -3,984,000 | 39,426,000 | -397,000 | -640,000 | -661,000 | -27,000 | 44,044,000 | -84,000 | 30,280,000 | 0 | -16,851,000 | -1,000 | -18,000 | -3,000 | 43,000 | 241,000 | 33,365,000 | 445,000 | 0 | -90,000 | 34,877,000 | 204,000 | 4,000 | 212,000 | 3,000 | 9,000 | -1,064,000 |
net decrease in cash and restricted cash | -9,283,000 | ||||||||||||||||||||||||||||
cash and restricted cash at the beginning of the period | 30,147,000 | ||||||||||||||||||||||||||||
cash and restricted cash at the end of the period | 20,864,000 | ||||||||||||||||||||||||||||
reconciliation of cash and restricted cash | |||||||||||||||||||||||||||||
cash | 20,600,000 | ||||||||||||||||||||||||||||
restricted cash | 264,000 | ||||||||||||||||||||||||||||
total cash and restricted cash | 20,864,000 | ||||||||||||||||||||||||||||
loss on disposal of fixed assets | 0 | 68,000 | -58,000 | 0 | 2,476,000 | ||||||||||||||||||||||||
change in obligation for r&d funding liability | |||||||||||||||||||||||||||||
non-cash r&d expense related to warrant vesting | |||||||||||||||||||||||||||||
impairment of right-of-use asset | -5,000 | ||||||||||||||||||||||||||||
loss on extinguishment of debt | 0 | ||||||||||||||||||||||||||||
purchases of property and equipment | 0 | -16,000 | -227,000 | -65,000 | -59,000 | -11,000 | -66,000 | -77,000 | -154,000 | -5,000 | -237,000 | -39,000 | -296,000 | -311,000 | -111,000 | -116,000 | -699,000 | ||||||||||||
sale of fixed assets | |||||||||||||||||||||||||||||
proceeds from exercise of stock options | 1,000 | 0 | 150,000 | 4,000 | 0 | 0 | 0 | 7,000 | 0 | 45,000 | 273,000 | 240,000 | 446,000 | 0 | 0 | 7,000 | 204,000 | 4,000 | 212,000 | 3,000 | |||||||||
proceeds from issuance of debt, net of issuance costs | 0 | ||||||||||||||||||||||||||||
proceeds from issuance of common stock, pre-funded warrants and warrants | |||||||||||||||||||||||||||||
issuance costs for common stock, pre-funded warrants and warrants | |||||||||||||||||||||||||||||
cash paid to settle debt | |||||||||||||||||||||||||||||
debt amendment costs | |||||||||||||||||||||||||||||
net decrease in cash and cash equivalents | 9,050,000 | 5,701,000 | |||||||||||||||||||||||||||
cash and cash equivalents at the beginning of the year | |||||||||||||||||||||||||||||
cash and cash equivalents at the end of the year | |||||||||||||||||||||||||||||
supplemental disclosures | |||||||||||||||||||||||||||||
cash paid for interest | 1,734,000 | 1,804,000 | 1,852,000 | 1,836,000 | 1,833,000 | 1,000 | 320,000 | 743,000 | 725,000 | 733,000 | 741,000 | 742,000 | 634,000 | 641,000 | 649,000 | ||||||||||||||
supplemental disclosure of noncash investing and financing activities: | |||||||||||||||||||||||||||||
recognition of r&d funding liability and deferred r&d services | |||||||||||||||||||||||||||||
non-cash accruals for equity issuance costs | |||||||||||||||||||||||||||||
right-of-use asset obtained in exchange for lease obligation | 0 | 563,000 | 220,000 | 1,193,000 | 1,312,000 | 0 | 0 | 0 | |||||||||||||||||||||
extinguishment of finance lease liability as a result of lease termination | |||||||||||||||||||||||||||||
extinguishment of operating lease liability as a result of lease termination | |||||||||||||||||||||||||||||
non-cash accretion of r&d funding liability | |||||||||||||||||||||||||||||
payment of debt amendment fees | -17,000 | -613,000 | -509,000 | ||||||||||||||||||||||||||
cash and cash equivalents at the beginning of the period | 0 | 0 | 0 | 69,547,000 | 0 | 0 | 0 | 10,686,000 | 0 | 0 | 9,241,000 | 0 | 0 | 10,271,000 | 0 | ||||||||||||||
cash and cash equivalents at the end of the period | 5,701,000 | -8,971,000 | -17,009,000 | 48,939,000 | 29,168,000 | -4,264,000 | -19,395,000 | 44,101,000 | -31,734,000 | -5,554,000 | 54,486,000 | -9,252,000 | -4,575,000 | 24,427,000 | -64,838,000 | ||||||||||||||
license and collaboration receivable, billed and unbilled | |||||||||||||||||||||||||||||
property and equipment purchases in accounts payable or accrued expenses and other current liabilities at period end | 3,000 | 11,000 | |||||||||||||||||||||||||||
finance lease liability extinguished as a result of lease termination | |||||||||||||||||||||||||||||
noncash interest expense | 472,000 | ||||||||||||||||||||||||||||
proceeds from issuance of common stock, pre-funded warrants and series a and b warrants, net of issuance costs | |||||||||||||||||||||||||||||
equity issuance costs | -84,000 | -28,000 | |||||||||||||||||||||||||||
net increase in cash and cash equivalents | 23,370,000 | -8,971,000 | -17,009,000 | -20,608,000 | 1,800,000 | -4,690,000 | -4,264,000 | -19,395,000 | 33,415,000 | -6,512,000 | -31,734,000 | -5,554,000 | 45,245,000 | -1,359,000 | -9,252,000 | -4,575,000 | 14,156,000 | -28,040,000 | -64,838,000 | ||||||||||
property and equipment purchases in accounts payable or accrued expenses and other current liabilities at year end | |||||||||||||||||||||||||||||
fair value of warrants issued with debt | |||||||||||||||||||||||||||||
collaboration revenue receivable, billed and unbilled | 99,000 | 409,000 | -424,000 | -117,000 | 431,000 | ||||||||||||||||||||||||
repayment of financing lease | 0 | -2,000 | -1,000 | -1,000 | -2,000 | -2,000 | |||||||||||||||||||||||
proceeds from issuance of common stock and pre-funded warrants, net of issuance costs | -1,000 | 0 | 0 | 30,301,000 | |||||||||||||||||||||||||
common stock warrants issued with debt | |||||||||||||||||||||||||||||
non cash interest expense | 483,000 | -242,000 | 326,000 | 300,000 | 352,000 | 336,000 | 393,000 | 269,000 | 263,000 | 65,000 | |||||||||||||||||||
amortization of premiums on marketable securities | 11,000 | 21,000 | 27,000 | 49,000 | |||||||||||||||||||||||||
gain on operating lease termination | |||||||||||||||||||||||||||||
unbilled receivable | -430,000 | -201,000 | 213,000 | -431,000 | |||||||||||||||||||||||||
sales and maturities of marketable securities | 7,000,000 | 2,008,000 | 2,492,000 | 47,508,000 | 14,200,000 | 19,200,000 | 15,100,000 | 20,500,000 | 12,100,000 | 13,394,000 | 20,000,000 | 24,355,000 | 24,500,000 | 22,650,000 | 28,200,000 | 42,365,000 | |||||||||||||
purchases of marketable securities | 0 | -8,000 | 8,000 | -4,485,000 | -9,828,000 | -12,870,000 | -36,931,000 | -9,285,000 | -12,193,000 | -37,409,000 | -16,754,000 | -5,382,000 | -16,623,000 | -23,999,000 | -27,937,000 | -21,295,000 | -20,496,000 | ||||||||||||
deposits | -141,000 | -5,000 | -124,000 | 0 | -8,000 | -69,000 | |||||||||||||||||||||||
debt issuance costs | 0 | 0 | 0 | -17,000 | 0 | ||||||||||||||||||||||||
change in unrealized loss on marketable securities | |||||||||||||||||||||||||||||
amortization in operating lease right-of-use asset | |||||||||||||||||||||||||||||
payment of debt issuance costs | |||||||||||||||||||||||||||||
net increase in cash, cash equivalents and marketable securities | 29,168,000 | -4,812,000 | 25,679,000 | ||||||||||||||||||||||||||
reduction in operating lease right-of-use asset | 72,000 | 71,000 | 69,000 | 65,000 | 60,000 | 57,000 | 57,000 | 56,000 | 19,000 | 45,000 | 66,000 | ||||||||||||||||||
property and equipment purchases payable or accrued at period end | 34,000 | -124,000 | 0 | -168,000 | 459,000 | 46,000 | -30,000 | -14,000 | 253,000 | -137,000 | 26,000 | 96,000 | 333,000 | ||||||||||||||||
cash, cash equivalents and marketable securities at the beginning of the period | 34,273,000 | ||||||||||||||||||||||||||||
cash, cash equivalents and marketable securities at the end of the period | 59,952,000 | ||||||||||||||||||||||||||||
gain on lease termination | |||||||||||||||||||||||||||||
proceeds from issuance of common stock, net of issuance costs | 0 | -1,000 | 0 | -31,000 | 28,150,000 | ||||||||||||||||||||||||
change in unrealized gain on marketable securities | -2,000 | -33,000 | -1,000 | -4,000 | 2,000 | -5,000 | -26,000 | -7,000 | -11,000 | ||||||||||||||||||||
net increase in cash, cash equivalents and restricted cash | -4,977,000 | 34,655,000 | |||||||||||||||||||||||||||
cash, cash equivalents and restricted cash at the beginning of the period | 0 | 15,752,000 | |||||||||||||||||||||||||||
cash, cash equivalents and restricted cash at the end of the period | -4,977,000 | 50,407,000 | |||||||||||||||||||||||||||
license receivable | -11,500,000 | ||||||||||||||||||||||||||||
amortization on operating lease right-of-use asset | 67,000 | 67,000 | 30,000 | 29,000 | |||||||||||||||||||||||||
debt issuance cost | |||||||||||||||||||||||||||||
repayment of subscription receivable | 0 | 0 | 0 | 410,000 | |||||||||||||||||||||||||
debt issuance costs included in accrued expenses at year end | |||||||||||||||||||||||||||||
accretion of discounts on marketable securities | 39,000 | -11,000 | -14,000 | -13,000 | -4,000 | -28,000 | -93,000 | -183,000 | -238,000 | -283,000 | -359,000 | -388,000 | |||||||||||||||||
proceeds from issuance of debt | 0 | 0 | 4,975,000 | 0 | 0 | 0 | 34,460,000 | ||||||||||||||||||||||
subscription receivable on exercise of options | |||||||||||||||||||||||||||||
debt issuance costs accrued at period end | |||||||||||||||||||||||||||||
debt discount costs included in accrued expense at period end | 125,000 | ||||||||||||||||||||||||||||
noncash interest expense on debt | |||||||||||||||||||||||||||||
accrued expenses | -1,448,000 | 88,000 | 1,143,000 | 4,000 | 171,000 | 46,000 | |||||||||||||||||||||||
accounts payable and accrued expenses - related party | 6,000 | -38,000 | 0 | 2,000 | |||||||||||||||||||||||||
purchases of property, plant and equipment | -3,000 | -151,000 | -13,000 | ||||||||||||||||||||||||||
increase in deposits | |||||||||||||||||||||||||||||
other non-current assets | |||||||||||||||||||||||||||||
other receivable - related party | -6,000 | ||||||||||||||||||||||||||||
proceeds from the issuance of common stock in connection with ipo | 0 | 0 | |||||||||||||||||||||||||||
payment of offering cost in connection with issuance of common stock in connection with ipo | 2,000 | -1,064,000 | |||||||||||||||||||||||||||
proceeds received from issuance of series c preferred stock | 0 | 0 | |||||||||||||||||||||||||||
stock issuance costs related to series c preferred stock | 0 | 0 | |||||||||||||||||||||||||||
supplemental disclosure of cash flow information: | |||||||||||||||||||||||||||||
conversion of preferred stock into common stock | 0 | 0 | |||||||||||||||||||||||||||
accrual for purchases of property, plant and equipment | |||||||||||||||||||||||||||||
security deposits | |||||||||||||||||||||||||||||
due to related party | |||||||||||||||||||||||||||||
proceeds from issuance of common stock in connection with ipo, net of offering costs | |||||||||||||||||||||||||||||
proceeds from issuance of series c preferred stock, net of issuance costs | |||||||||||||||||||||||||||||
construction in process purchases payable or accrued at period end | |||||||||||||||||||||||||||||
payment of offering costs in connection with issuance of common stock in connection with ipo | |||||||||||||||||||||||||||||
fixed asset and construction in process purchases payable or accrued at period end | |||||||||||||||||||||||||||||
issuance costs included in accounts payable and accrued expenses | |||||||||||||||||||||||||||||
fixed asset and construction in process purchases accrued at period end | 285,000 | ||||||||||||||||||||||||||||
deferred offering costs included in accounts payable and accrued expenses | |||||||||||||||||||||||||||||
deposit for construction of equipment | |||||||||||||||||||||||||||||
proceeds received from series a preferred stock subscription receivable | |||||||||||||||||||||||||||||
stock issuance costs related to series a preferred stock | |||||||||||||||||||||||||||||
fixed asset purchases accrued at period end |